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ABSTRACT
Nuclear erythroid related factor-2 (NRF2) is known to promote cancer therapeutic 
detoxification and crosstalk with growth promoting pathways. HER2 receptor tyrosine 
kinase is frequently overexpressed in cancers leading to uncontrolled receptor 
activation and signaling. A combination of HER2 targeting monoclonal antibodies 
shows greater anticancer efficacy than the single targeting antibodies, however, its 
mechanism of action is largely unclear. Here we report novel actions of anti-HER2 
drugs, Trastuzumab and Pertuzumab, involving NRF2.
HER2 targeting by antibodies inhibited growth in association with persistent 
generation of reactive oxygen species (ROS), glutathione (GSH) depletion, reduction 
in NRF2 levels and inhibition of NRF2 function in ovarian cancer cell lines. The 
combination of antibodies produced more potent effects than single antibody alone; 
downregulated NRF2 substrates by repressing the Antioxidant Response (AR) 
pathway with concomitant transcriptional inhibition of NRF2. We showed the antibody 
combination produced increased methylation at the NRF2 promoter consistent with 
repression of NRF2 antioxidant function, as HDAC and methylation inhibitors reversed 
such produced transcriptional effects. These findings demonstrate a novel mechanism 
and role for NRF2 in mediating the response of cancer cells to the combination of 
Trastuzumab and Pertuzumab and reinforce the importance of NRF2 in drug resistance 
and as a key anticancer target.
INTRODUCTION
Nuclear erythroid related factor-2 (NRF2) is a 
leucine zipper transcription factor and the master regulator 
of the antioxidant response (AR) pathway. It drives both 
basal and oxidative stress-induced transcription of a 
battery of phase I, II, and III detoxification enzymes and 
cytoprotective genes [1–3], as well as other genes of the 
metabolic and signal transduction pathways [2–4]. This 
is achieved by its binding to cis-acting factors called 
Antioxidant Response Elements (AREs) or electrophile 
response elements (EpREs) within the promoters of its 
target genes [5]. Under basal conditions, a low level of 
free NRF2 is available in the cytoplasm where some 
translocates into the nucleus to drive the basal transcription 
of target genes. Much of the remaining cytosolic NRF2 is 
held by Kelch-like ECH-associated protein 1 (KEAP1), 
a cytoplasmic NRF2-binding adaptor that primes NRF2 
for degradation via 26S proteasome [6, 7]. Following 
oxidative stress or in the presence of NRF2 activators, 
a number of cysteine residues within KEAP1 become 
oxidized causing conformational changes in the KEAP1 
structure. This disables KEAP1 to bind additional NRF2 
and cause its degradation leading to nuclear accumulation 
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of NRF2, activation of its transcriptional function to 
induce transactivation of ARE-containing genes and 
finally restoration of cellular redox homeostasis [8].
Hyperactivation of NRF2 is also a recognized 
intermediate in cellular proliferation and in conferring 
therapeutic resistance to cancers [9–11]. Specifically, 
NRF2 activation and KEAP1 inactivation mutations are 
harbinger to permanent constitutive activation of the NRF2 
dependent AR pathway now frequently observed in cancers 
[12–15]. Furthermore, several therapeutic strategies such 
as anticancer radio- and chemo-therapy largely depend 
on reactive oxygen species (ROS) generation to induce 
cytotoxicity. Thus, hyper-activation of NRF2 dependent 
AR pathway would attenuate the potency of such agents. 
Moreover, NRF2 is directly involved in the regulation of 
apoptosis and proliferation [16, 17].
The HER receptor network contains four members 
(HER1, HER2, HER3 and HER4) belonging to the family 
of Receptor Tyrosine Kinases (RTKs), which are key 
regulators of cellular proliferation, differentiation and 
survival [18–21]. Activation of RTKs involves ligand 
dependent homo- and hetero-dimerization and stimulation 
of their intrinsic tyrosine kinase activity that leads to the 
phosphorylation of tyrosine residues in the intracellular 
domain of these receptors. The phospho-tyrosine residues 
serve as docking sites to recruit a number of signal adapter 
proteins containing specific domains called SH2- and 
PTB. Through these domains, RTK links its activation 
with different cellular signaling pathways such as PI3K/
AKT/mTOR, MAPK, and STAT [22, 23]. The activation 
kinetics and strength of the HER receptor network depend 
significantly on the expression levels, which vary across 
different cells and cancers [24]. Likewise it is these 
variations in expression combined with their context 
dependent preferences for dimerization partners and 
ligand dependent or independent signaling modes that 
cause complexity in fully elucidating the activation and 
functioning of the HER receptor family.
The HER2 and HER3 receptors are non-autonomous 
and possess certain defining features, in that HER2 has 
auto-kinase activity but no known ligands, whereas HER3 
is a pseudo-kinase receptor that lacks tyrosine kinase 
activity. These features dictate the interaction between 
the HER2 and HER3 receptors and for forming active 
heterodimer complexes. Mutation or increased gene copy 
number leads to hyper-activation or overexpression of 
HER receptors respectively. These mechanisms lead to 
receptor auto-phosphorylation and constitutive activation, 
enabling cells to lose their requirement for ligand and/or 
hetero-dimerization of receptors, mechanisms which elicit 
uncontrolled proliferative pathways ultimately converting 
normal cells into malignant cells [18, 22, 23, 25, 26]. 
Among the RTK kinase family members, HER2 has 
gained major importance as an anticancer drug target. This 
is owing to this receptor frequently being overexpressed in 
certain cancer types and partners with the HER3 receptor, 
a combination, which is known to strongly elicit robust 
growth-promoting pathways [27–33].
HER2 targeting immunotherapeutic agents, 
comprising of HER2 specific humanized monoclonal 
antibodies, Pertuzumab and Trastuzumab (Herceptin), have 
acquired a central position as targeted anticancer modalities 
and are currently being extensively studied [31, 32]. These 
monoclonal antibodies frequently have limited effectiveness 
in combating cancers as tumor cells circumvent the action of 
the single agents due to the readjustments in co-expression 
of HER2/HER3 receptors, their ligand binding dynamics 
or changing preference for the dimerizing partners [25, 34, 
35]. Because of such complexity, it is imperative to identify 
and characterize downstream pathway nodes where RTK 
signaling converges, in order to identify novel druggable 
targets to exploit during immunotherapies involving HER2 
inhibition.
Recently, a growing body of evidence has 
implicated coregulatory roles of HER2/HER3, NRF2 and 
ROS in the promotion of cellular proliferation, increased 
detoxification potential and therapeutic resistance in 
cancer cells [36–39]. Specifically, generation of ROS, 
which is a key regulator of the NRF2 pathway [40], has 
been demonstrated as a regulator of the HER2/HER3 
complex and subsequent activation of their functions 
[41]. Elucidation of these new mechanisms place ROS 
at a central position where it might act as a point of 
convergence of these two cytoprotective pathways. 
Moreover, studies have also shown direct mechanisms of 
activation of NRF2 by components of the RTK pathway 
such as PI3K and MAPK [42, 43], whereas many aspects 
of RTK signaling are regulated by ROS, whose levels 
are directly modulated by NRF2 function [44]. We have 
recently shown that NRF2 regulates the expression of 
HER2 and HER3 to modulate HER2/HER3 targeted 
immunotherapy against ovarian cancer cells [45]. 
We have also shown the ROS-dependent hierarchical 
addiction and manipulation strategy of these cancer 
cells to draw proliferative advantage [10, 11]. This led 
us to hypothesize that inhibition of NRF2 function and 
concomitant cellular accumulation of ROS are possible 
mechanistic components and basis of action of HER2-
targeted immunotherapy.
In this study, we have elucidated a new 
mechanism of action of the combination of anticancer 
immunotherapeutic agents. We demonstrate that 
combination treatment with HER2 targeting monoclonal 
antibodies, Pertuzumab and Trastuzumab, causes 
inhibition of NRF2 function and subsequent repression of 
NRF2 dependent antioxidant response pathway in human 
ovarian cancer cell lines. This repressive action on NRF2 
not only defined the overall sensitivity towards targeted 
therapy, but could also be modulated to further enhance 
this sensitivity in otherwise resistant ovarian cancer 
cells. Furthermore, we present evidence and describe 
an epigenetic mechanism of transcriptional repression 
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of NRF2, which involves promoter methylation and 
gene silencing following combination of Pertuzumab 
and Trastuzumab treatment. Thus we reveal that the 
effectiveness and enhanced cytotoxic action of the 
combination of HER2 targeted immunotherapeutic agents 
can be at least partly explained by their ability to cause 
transcriptional inhibition of NRF2 and greater repression 
of its antioxidant function in low, moderate and high 
HER2 expressing ovarian cancer cell lines. As such, 
this study expands the role of NRF2 as a key element 
in driving drug resistance and offers a novel strategy of 
cancer cell sensitization during the course of targeted 
therapy for cancer employing immunotherapeutics.
RESULTS
Action of targeted immunotherapeutic agents 
involves generation of ROS, which contributes to 
cancer growth inhibition
Reactive oxygen species (ROS), while traditionally 
considered as cellular by-products of metabolism, have 
gained enormous importance in the past decade and 
are further recognized as second messengers in signal 
transduction processes influencing growth, survival and 
overall physiological homeostasis [46–48]. Furthermore, 
there are several previous studies that have illustrated 
the co-modulatory role and interaction of ROS with RTK 
receptors and growth promoting pathways [49–52]. These 
taken together with our recent work (10, 11, 45) have led 
us to hypothesize that inhibition of NRF2 function and 
concomitant cellular accumulation of ROS are possible 
mechanistic components and basis of action of HER2-
targeted immunotherapy. To address this hypothesis we 
first studied total ROS levels in basal, Heregulin (HRG) 
stimulated and drug-inhibited states in three cell lines. 
HRG is a growth factor belonging to the EGF family. We 
used HRG as it is a potent ligand for HER receptors and 
causes HER2-HER3 dimerization [20]. We used a low 
HER2 expressing ovarian cancer cell line, OVCAR4, 
a moderately HER2 expressing PEO4 and a HER2 
overexpressing cell line, SKOV3 [34].
Data in Figure 1A illustrate that HRG stimulation 
alone led to a significant and sustained increase in ROS 
levels in all three cell lines as compared to basal levels 
in unstimulated cells. More importantly, we saw that 
treatments with Pertuzumab, Trastuzumab or their 
combination led to ROS generation in our ovarian cancer 
cell line models. ROS elevation was seen at all the time 
points tested but these were consistently significant in 
PEO4 cells and more restricted in OVCAR4 (Figure 1B). 
Within single agent treatments, in PEO4, Pertuzumab 
generated more ROS than Trastuzumab while in OVCAR4 
and SKOV3, Trastuzumab consistently generated higher 
ROS than Pertuzumab alone.
We then further investigated the contribution of ROS 
generation in the mechanism of cytotoxic action of these 
immunotherapeutic agents. To address this, we repeated 
our cytotoxicity experiment but this time co-treated cells 
with the ROS scavenger, N-acetyl Cysteine (NAC) in order 
to neutralize ROS and then study its consequences on 
survival for different time points of treatment. Strikingly, 
we found that neutralization of ROS in all the cell lines 
significantly improved survival following drug treatments 
(Figure 1C), especially at later time point and perhaps 
following the uptake and channeling of NAC in de novo 
GSH synthesis. Consistent with our previous conclusions, 
NAC dependent protection was more pronounced and 
sustained in the PEO4 cell line and with Pertuzumab and 
combination treatments, whereas for OVCAR4, NAC was 
more protective following Trastuzumab and combination 
treatment. Interestingly, NAC treatment of SKOV3 
cells exerted limited protection against cytotoxic action 
of the inhibitors (Figure 1C). These observations are of 
significance, as they clearly illustrate the role of ROS 
and hence of the overall antioxidant potential of cancer 
cells in determining sensitivity to otherwise unrelated 
immunotherapeutic agents. The fact that receptor 
inhibition led to generation of ROS (Figure 1B) and that 
this ROS was a contributing factor in cellular cytotoxicity 
(Figure 1C) implicated the engagement of antioxidant 
pathway during drug action. Thus, we next sought to 
investigate the status of the NRF2-KEAP1antioxidant 
response of these cancer cells following the HER2/HER3 
targeted immunotherapies. In order to further support and 
confirm this role, we performed additional experiments as 
described below.
Inhibition of NRF2 by Retinoic acid (RA) 
disrupts its antioxidant transcriptional program, 
suppresses NRF2 and HO-1 protein levels, 
elevates cellular ROS and enhances cytotoxicity 
of the immunotherapeutic agents
Retinoic acid (RA) has previously been shown 
to inhibit the antioxidant response (AR) pathway in an 
NRF2 dependent manner [53]. In order to extend the 
observations reported in the previous section, we wanted 
to study the consequences of NRF2 inhibition on survival 
following exposure to the HER2 targeting drugs. Firstly, 
we did a series of experiments in the ovarian cancer cell 
line models in order to validate and confirm the inhibitory 
action of RA on the NRF2 dependent AR pathway. 
Exposure to RA alone caused a decrease in total NRF2 
levels (Figure 2A). Interestingly the levels of NRF2 
in these cell lines were further decreased following co-
treatment with combined immunotherapy (Trastuzumab & 
Pertuzumab). This drug induced reduction in NRF2 levels 
suggested that immunotherapy is also targeting NRF2. 
Next, using the luciferase ARE reporter AREc32 cell line, 
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we demonstrated that RA treatment significantly inhibited 
transcriptional activity of NRF2 at all the time points 
tested (Figure 2B). RA treatment of AREc32 reporter cell 
line also elevated ROS levels (Supplementary Figure S1). 
Furthermore, RA could not further enhance the inhibitory 
action of combination of immunotherapeutic agents on 
AR pathway. We also examined the effect of RA treatment 
at single cell level on NRF2 substrate, HO-1, and could 
demonstrate a decrease in its abundance (Figure 2C). 
These findings suggested that while RA inhibits NRF2 
dependent AR pathway, such treatment might also elevate 
cellular ROS levels in the ovarian cancer cell lines. Indeed 
we found that treatment with RA significantly induced 
ROS in the three cell lines tested (Figure 3A and 3B).
We next asked whether RA dependent inhibition 
of NRF2 AR pathway would sensitize ovarian cancer 
cells to targeted immunotherapeutic agents and if such 
treatment could achieve sensitization in the otherwise drug 
resistant OVCAR4 cell line. To do this, we repeated drug 
treatments either alone or in combination for 24-96 h, but 
this time with co-treatment of RA (Figure 3C). We found 
significantly enhanced cytotoxicity of targeted therapies 
following NRF2 inhibition in all three cell lines, in all 
treatments and at most time points tested. PEO4 cell line 
was most sensitized to such treatments with all groups 
showing significant increase in cell death. OVCAR4, 
which was more resistant, was also sensitized to targeted 
therapies following RA treatment. We also determined 
whether treatment with RA in the absence of any other 
drugs alone could curb cancer growth, and thus analyzed 
growth rates for 4 days and found growth inhibition 
(Supplementary Figure S2). These findings illustrated 
the important role of NRF2 in influencing outcomes to 
targeted therapies involving HER2 receptor inhibition.
These results indicate that effectiveness of anticancer 
therapy involving targeted immunotherapeutic agents could 
be enhanced by parallel inhibition of the NRF2 dependent 
antioxidant response pathway. As such, this represents a 
novel drug target in the context of HER2 inhibition and 
could explain the enhanced effectiveness of combination 
of Pertuzumab and Trastuzumab, a treatment that reduced 
NRF2 levels, as opposed to single agents. This could 
Figure 1: Treatment with HER2 targeting antibodies generates Reactive Oxygen Species (ROS) that when neutralized 
leads to cytoprotection in ovarian cancer cells. A. Heregulin treatment causes persistent elevation of ROS in ovarian cancer cells. 
Exponentially growing cells were seeded in triplicates in opaque flat bottom black walled 96-well plates for 24 h. Following this, cells were 
either left untreated (UT) or treated with 1nM Heregulin for different time points as indicated. Following incubations, cells were loaded 
with DCFDA fluorescent stain for 45 min and assayed for ROS as described in Materials and Methods. B. HER2 targeting monoclonal 
antibodies cause ROS generation. Cells were seeded as in (A) and treated with either 1nM HRG alone or with co-treatment of 20μg/mL 
Pertuzumab (PR), Trastuzumab (TR) or their combination (COMB) for different time points as indicated and ROS assay was repeated. 
For both (A) and (B), the fluorescence reading recorded from each well was normalized to total cell abundance within the same wells 
as described in Materials and Methods. C. Treatment with N-Acetyl Cysteine (NAC) desensitizes ovarian cells to immunotherapeutic 
agents targeting HER2. Cells were seeded as in (A) and either left untreated in media containing 1nM Heregulin (HRG) or treated with 
same media containing 20μg/mL of HER2 inhibitors, Pertuzumab and Trastuzumab either alone or in combination (RTKi only group) or 
in the continuous presence of 10mM NAC (RTKi + NAC group). Cells were treated with the MTT reagent as described in Materials and 
Methods and OD readings were obtained. Data shown are mean values ± S.D of triplicates, normalized to UT in (A) or HRG in (B) and 
(C) and expressed as fold change. Statistical significance was determined between treatment groups either by independent t test or ONE 
WAY ANOVA followed by post hoc Tukey’s test as appropriate and significance expressed according to the scale * P <0.05, **P <0.01, 
***P <0.001.
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further serve to explain why HER2 immunotherapeutics in 
certain contexts show poor efficacy.
Action of targeted immunotherapeutic agents 
involves repression of NRF2-dependent 
transcription and depletion of total Glutathione
Having observed additional decreased levels of NRF2 
in these cell lines following combined immunotherapy 
(Trastuzumab & Pertuzumab) with RA treatments, we next 
asked whether targeted immunotherapy would also inhibit 
NRF2-dependent transcription. To address this, we used 
the AREc32 cell line, stably expressing 8 copies of NRF2 
dependent cis-regulatory antioxidant response elements, as 
a luciferase reporter. We found that while HRG stimulation 
alone induced the antioxidant response pathway, co-
treatment with combination of Pertuzumab and Trastuzumab 
not only disrupted such induction, but further suppressed 
Figure 2: Treatment with Retinoic acid (RA) causes inhibition of NRF2 dependent antioxidant response pathway and 
generates ROS. A. Western analysis showing repression of NRF2 levels following RA treatment in PEO4, OVCAR4 and SKOV3 cell 
lines. Exponentially growing cells were either left untreated, treated with 2.5μM RA or a combination of 2.5μM RA together with 20μg/
mL of Pertuzumab and Trastuzumab for 96 h before being harvested to prepare protein lysates and processed as described in Materials and 
Methods. Ponceau stain of the same blot was used as loading control. Red bars indicate NRF2 levels following quantification of immunoblot 
signal intensities obtained in (A) and normalized to the value of UT and expressed as fold change. The signal intensities of bands were 
quantified through integrated optical densitometry measurement. B. RA treatment causes inhibition of NRF2 dependent transcription. 
Exponentially growing AREc32 cell line stably expressing 8xcis-antioxidant response elements driving the expression of luciferase gene 
in an NRF2 dependent manner were either left untreated (UT), treated with RA alone, or with RA and combination of Pertuzumab and 
Trastuzumab for different time points as indicated. Following this, cell lysates were prepared and assayed for Luciferase activity (BrightGlo 
Luciferase system, Promega). Data are the mean values ± S.D of quadruplicates, normalized to untreated (UT) and expressed as fold 
change with statistical significance determined by ONE WAY ANOVA followed by Tukey’s post hoc test according to the scale * P <0.05, 
**P <0.01, ***P <0.001. C. RA treatment causes repression of HO-1 levels. Immunofluorescent labelling of endogenous HO-1 in cells 
previously grown on poly-L lysine coated coverslips and exposed to RA treatment as in (A). For immunolabelling, primary HO-1 antibody 
followed by Alexa Fluor® 568 conjugated secondary antibody (red fluorescence) was used. Nuclear reference was provided by co-staining 
with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica DMiRe2 electronic microscope using 
integrated features of ANDOR iQ core software (ANDOR Technologies Ltd). Scale bar indicates 10μm. These are representative images 
taken in different field of views with relevant fluorescence channels and 100x objective.
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it significantly at 24 and 72 h of treatment (Figure 4A). 
Treatments with single agents alone also inhibited NRF2 
function, although to a lesser extent than their combination.
We next asked whether NRF2 repression would 
also lead to depletion of total cellular glutathione. A 96 
h treatment with HRG induced total cellular glutathione, 
while combination of Pertuzumab and Trastuzumab 
significantly reduced this level in PEO4 cells. The same 
was seen for OVCAR4 and SKOV3 cells, albeit not 
significantly (Figure 4B). These studies demonstrate that 
HER2 targeting monoclonal antibodies repress the NRF2 
dependent antioxidant pathway which may well contribute 
to the unique enhanced cytotoxicity in the combination of 
Pertuzumab and Trastuzumab.
Ovarian cancer cells exhibit different 
degrees of cytotoxicity to HER2 targeting 
immunotherapeutic agents Pertuzumab and 
Trastuzumab
We next determined the degree of sensitivity of 
ovarian cancer cells derived from different origins to the 
HER2 targeting monoclonal antibodies, Pertuzumab and 
Trastuzumab, either used individually or in combination 
(Figure 5A). To do this, we again used the low HER2 
expressing ovarian cancer cell line, OVCAR4, the 
moderately HER2 expressing PEO4 and the HER2 
overexpressing cell line, SKOV3 [34]. Moreover, the 
expression of the HER2 key heterodimerization partner, 
HER3, is variable in these ovarian cell lines with PEO4 
expressing the highest, OVCAR4 moderate and SKOV3, 
the lowest [34]. We found that not only did the cells 
exhibit variable and statistically significant and distinct 
susceptibilities to the monoclonal antibodies, but that they 
also exhibited time dependent variation in sensitivities 
(Figure 5A). For example, within single treatments, while 
Pertuzumab was more cytotoxic (than Trastuzumab) to 
PEO4 cells, Trastuzumab achieved greater cytotoxicity 
in OVCAR4 and SKOV3 cell lines. Secondly, with each 
treatment modality, growth inhibition was maximal 
following 72 h of treatment. Thirdly, the combination 
treatment, having both Pertuzumab and Trastuzumab, 
was generally more cytotoxic than single agents in all 
cell lines. Finally, overall, PEO4 was found to be more 
Figure 3: Inhibition of NRF2 pathway by Retinoic acid (RA) sensitizes ovarian cancer cells to immunotherapeutic 
agents targeting HER2 by increased ROS and enhanced growth inhibition. A. RA treatment causes increase in ROS levels. 
Exponentially growing cells were seeded in triplicates in opaque flat bottom black walled 96-well plates for 24 h. Following this, cells 
were either left untreated (UT) or treated with 1nM Heregulin and exposed to 2.5μM RA for different time points as indicated. Following 
incubations, cells were loaded with DCFDA fluorescent stain for 45 min and assayed for ROS by measuring fluorescence as described 
in Materials and Methods. Data is shown as fold change of RA treated cells to UT or RA and HRG treated cells to HRG treated cells as 
indicated (broken line). B. Green fluorescent signal of DCFDA stain indicating ROS accumulation in ovarian cancer cells. Exponentially 
growing cells were either left untreated in media containing 1nM Heregulin (HRG) in the presence 5% charcoal stripped FBS, or treated 
with same media containing 20μg/mL of HER2 inhibitors, Pertuzumab and Trastuzumab either alone or in combination (RTKi only group) 
or in the continuous presence of 2.5μM RA (RTKi + RA group). Following treatments, cells were washed with PBS and imaged using 
Leica DMiRe2 electronic microscope and 485/535nm filter set. Merging with bright field phase contrast images captured in same field of 
view were performed by using integrated features of ANDOR iQ core software (ANDOR Technologies Ltd). Scale bar indicates 50μm. 
These are representative images with a 40x objective. C. Growth inhibition measured using the MTT assay as described in Materials and 
Methods. Values are mean values ± S.D of triplicates and expressed as fold decrease to HRG. Statistical significance was determined 
between pairs of RTKi only and RTKi + RA groups by independent t test and significance expressed according to the scale * P <0.05, 
**P <0.01, ***P <0.001.
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sensitive to combination of the drugs, SKOV3 showed 
moderate sensitivity while OVCAR4 was least sensitive 
(Figure 5A).
This analysis revealed the differential responses 
of the tested ovarian cancer cell lines to the same HER2 
inhibitors indicating the variable nature of outcomes to 
targeted therapy involving HER2 inhibitors. However, 
since most of the time points tested revealed the 
combination of the two inhibitors produced the highest 
growth inhibition, this initial cytotoxicity data supports 
the use of the combination treatment in ovarian cancer 
[31, 33].
Pertuzumab and Trastuzumab produce different 
levels of RTK signaling inhibition in ovarian 
cancer cell lines
Upon observing varying degrees of growth 
inhibition to Pertuzumab and Trastuzumab in the three 
cell lines used, we next sought to determine whether these 
also achieve different degrees of RTK signaling inhibition. 
Specifically, we determined the levels of phosphorylated 
forms of HER2 Thr 877 (pHER2) and AKT Ser 473 
(pAKT) following 96 h treatment with the HER2 targeting 
agents (Figure 5B).
Figure 4: Treatment with Pertuzumab and Trastuzumab causes repression of NRF2 dependent transcription and 
depletion of total Glutathione levels. A. Combination of Pertuzumab and Trastuzumab cause inhibition of NRF2 dependent 
transcription. Exponentially growing AREc32 cell line stably expressing cis-regulatory antioxidant response elements driving the expression 
of luciferase gene in an NRF2 dependent manner were treated with 1nM HRG alone or with co-treatment of 20μg/mL Pertuzumab and 
Trastuzumab either individually or in combination for different time points as indicated. Following this, cell lysates were prepared and 
assayed for Luciferase activity as described in Materials and Methods. Data shown are mean values ± S.D of quadruplicates, normalized 
to untreated (UT) and expressed as fold change with statistical significance determined by ONE WAY ANOVA followed by Tukey’s post 
hoc test. In upper panel, asterisks indicate significant difference in inhibition between monotherapy and combination while the # notation 
indicates the significant difference of inhibition between HRG and all the treatment types. In lower panel, asterisks indicate significant 
differences between individual groups as indicated and according to the scale * P <0.05, **P <0.01, ***P <0.001. B. Combination of 
targeted immunotherapeutic agents causes glutathione depletion. Exponentially growing cells were seeded in 60mm tissue culture plates 
for 24 h and either left untreated (UT) or treated with media containing 1nM Heregulin alone (HRG) or with co-treatment of 20μg/mL 
Pertuzumab (PR), Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested to prepare protein lysates and processed 
for glutathione assay. Data were normalized to the total protein content from same plates determined by Bradford assay and are mean values 
± S.D of triplicates and expressed as fold change to the UT. Statistical significance was determined by ONE WAY ANOVA followed by 
Tukey’s post hoc test according to the scale * P <0.05, **P <0.01, ***P <0.001.
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At 96 h, there was more marked repression of 
pHER2 and pAKT in the PEO4 cell line than either 
OVCAR4 or SKOV3 cells, consistent with the observation 
of increased sensitivity of PEO4 to these inhibitors. 
Furthermore, treatment with a combination of the two 
agents usually achieved the highest inhibition of RTK 
signaling, again consistent with the highest growth 
inhibition seen in combination treatment in Figure 5A. 
Finally and again consistent with Figure 5A, OVCAR4 
was found to have least inhibition of the phosphorylated 
substrates at all time points tested.
NRF2 is a master regulator of the antioxidant 
response (AR) pathway [7], while KEAP1 is its main 
regulator by functioning as an adaptor for ubiquitin 
ligase complex and promoting NRF2 degradation [54]. 
In the context of targeted immunotherapy, recent reports 
have suggested a role for NRF2 in determining overall 
treatment response [37, 55, 56]. More specifically, several 
studies have either suggested direct cross talk of NRF2 
and RTK signaling [36], or modulation of NRF2 by 
the RTK substrates PI3K [57–59] and MAPK [42, 43]. 
Furthermore, both RTK mediated growth promoting 
pathways and NRF2 dependent antioxidant responses 
have been documented to lead to drug resistance of cancer 
cells [60–64]. In light of these emerging roles of NRF2 in 
determining overall treatment responses, we next extended 
our investigation to study regulation of NRF2 and its 
degrader, KEAP1, in response to targeted therapies.
Treatment with HER2 inhibitors either alone or in 
combination on the contrary reduced NRF2 levels equally 
in our cell lines, consistent with previous studies [36]. 
The combination treatment caused a distinct repression in 
NRF2 levels in all three cell lines as compared to HRG 
treatment alone, whereas at the same time point, there 
Figure 5: Treatment with Trastuzumab and/or Pertuzumab causes cytotoxicity and modulates expression of pHER2, 
pAKT, NRF2 and KEAP1 in ovarian cancer cell lines. A. Effect of antibodies on cell number. Cells were treated with Pertuzumab 
(PR), Trastuzumab (TR) or combination (COMB) of antibodies in the presence of 1nM Heregulin. Antibodies were used at 20μg/mL. After 
treatment, cell number was assessed by use of the MTT assay as described in Materials and Methods. Values are means with ± S.D of 
triplicates and expressed as fold decrease to HRG alone. Statistical significance was determined between untreated and treated groups by 
ONE WAY ANOVA followed by Tukey’s post hoc test. Asterisks indicate significance of difference between HRG and individual treatment 
group whereas “#” indicates significance of difference between combination and Pertuzumab (red sign) or combination and Trastuzumab 
(blue sign) according to the scale * P <0.05, **P <0.01, ***P <0.001. B. Western blot analysis showing levels of phospho HER2 T877 
and phospho AKT S487 and C. NRF2 and KEAP1 in response to treatments with 20μg/mL of Pertuzumab (Pr), Trastuzumab (Tr) and 
their combination (Comb) in PEO4, OVCAR4 and SKOV3 cells. Exponentially growing cells were treated with media containing 1nM 
Heregulin alone, or with co-treatment of Pertuzumab, Trastuzumab or their combination for 96h before being analyzed as described in 
Materials and Methods. The bar charts show phospho HER2 or NRF2 (red bars) and phospho AKT levels or KEAP1 (blue bars) following 
quantification of the immunoblot signal intensities obtained and normalized to HRG treatment group and expressed as fold change. The 
signal intensities of bands were quantified through integrated optical densitometry measurement using Gelpro software (Version 3.1, Media 
Cybernetics).
Oncotarget9www.impactjournals.com/oncotarget
was induction of KEAP1 in PEO4 and SKOV3 cell lines 
(Figure 5C). Both NRF2 repression and KEAP1 induction 
were greater in PEO4 and SKOV3 cell lines than in 
OVCAR4, consistent with the cytotoxicity profiling 
(Figure 5A). NRF2 is implicated in numerous contexts 
in causing drug resistance [62–65] and the observed 
repression of NRF2 following combination treatment and 
greater repression in more sensitive cell lines is again 
consistent with a role for NRF2 in determining sensitivity 
to these targeted agents.
To characterize these observations further in an 
in vivo context, we performed extensive bioinformatic 
analysis and data mining from in vivo SKOV3 xenograft 
model previously exposed to same HER2 target 
immunotherapies. We especially sought to determine the 
precise mechanism of combination-induced repression of 
NRF2 and its antioxidant function.
Genetic reprogramming and NRF2 signaling 
following in vivo anti-HER2 immunotherapy
We recently reported on some genetic cellular 
reprogramming events following HER2-targeted 
immunotherapy with Trastuzumab or Pertuzumab and 
their combination in an in vivo xenograft model of 
ovarian cancer [25, 32]. We re-examined the expression 
profile and microarray data previously reported [32, 48]. 
However, this time we digressed from global analysis of 
gene expression and focused on the NRF2 network using 
a knowledge-based approach that is largely informed 
by information reported in [50–54]. We analyzed gene 
expression data as before [28, 32] on the response of 
SKOV3 xenograft tumors to Trastuzumab, Pertuzumab, 
and their combination treatments in the context of dynamic 
changes in the NRF2 network and signaling pathway.
A total of 3599 transcripts of 2250 genes linked to 
the NRF2 network and function were identified in the array 
with 14, 15 and 24% either upregulated or down regulated 
significantly (p≤0.05) following Trastuzumab, Pertuzumab 
and combination of the HER2-targeted immunotherapies 
(Figure 6A; Supplementary Table S1 and S2). The volcano 
plots illustrated in Figure 6B–6D indicate transcripts of 
genes within the NRF2 network. Strikingly, we identified 
significant changes in expression within the genes of 
the NRF2 network following immunotherapies relative 
to control values. Many of the differentially expressed 
genes in the NRF2 network due to combination treatment 
were already modulated by either Trastuzumab and/
or Pertuzumab monotherapy. The Pertuzumab and 
combination treatments produced greater effects in gene 
expression changes in ascending order of magnitude 
relative to Trastuzumab, both in terms of significant 
(p≤0.05) down- and up-regulation of genes (Figure 6E 
and 6F; Supplementary Table S1 and S2). Specifically 
some of these transcripts were significantly down 
regulated (p≤0.05) following immunotherapy of which 
87, 121, and 220 were due to Trastuzumab, Pertuzumab 
and combination of respectively. Furthermore, a total of 
19, 31, and 56 genes and transcripts were commonly and 
significantly down regulated (p≤0.05) by Trastuzumab 
and Pertuzumab, by Pertuzumab and combination, 
and by Trastuzumab and combination, respectively. 
The significant down regulation (p≤0.05) of 26 genes 
was common to both single and combination therapies. 
Irrespective of either monotherapy or combination 
therapy, within the NRF2 network, the total up- and down-
regulated genes, especially of the significant ones (p≤0.05) 
by each therapy were closely balanced and symmetrical 
(Figure 6B–6D, also see Supplementary Table S2). 
However, significantly greater volcanicity was observed 
with combination immunotherapy. Overall a total of 309, 
354, and 540 genes were significantly affected (p≤0.05) 
by Trastuzumab, Pertuzumab, and their combination, 
which accordingly represent 1:1.2:1.8 fold differences in 
the number of affected genes within the NRF2 network 
following these immunotherapies, respectively. We could 
visualize these significant changes in the NRF2 network 
using heatmaps, however, due to the large number of 
the genes affected, we chose to present only the filtered 
heatmap showing genes that remained significant even at 
p=0.001 (Figure 6A). The higher number of modulated 
genes recorded with the combination therapy relative to 
the monotherapies is indicative of a more complex gene 
expression changes and cellular reprogramming events, 
which led to the observed greater cellular ROS production 
and compromise of cellular NRF2 levels and functions.
More specifically, genes within the NRF2 network 
that were markedly expressed and down regulated 
following combination immunotherapy were detoxification 
and metabolism related AKR1B1, AKR1C1, ATP13A3, 
ATP1B1, ATP2A1, HMOX1, NQO1, FRMD6, GAPDH, 
GCLM, GCSH, GSTM4, H6PD, IDH1, PRDX1, SOAT1, 
SOD2, UGDH; DNA damage and repair related MLH3, 
MSH6, MYH4; cell signaling, proliferation, inflammation 
and immunity, and angiogenesis, related AKT3, AKTIP, 
CDH6, CXXC5, CXCL2, GSK3A, GSK3B, HACE1, 
ID1, KIT, KITLG, OSMR, PIK3AP1, PIK3IP1, PIK3R2, 
PIK3R5, RPS6KB1; EPHA2, FGF12, FGFBP1, FOS, 
FOSL2, FSTL1, IGF2BP3, JUNB, MAPK1, NGF, PDGFA, 
PDGFC, PDGFD, TGFA, TNFRSF1A, TAX1BP1, TUBB3, 
VEGFA, cell cycle regulation, cell survival and death 
related BAD, BARD1, BCL6, BCL2L15, BNIP1, CDK7, 
CDKN3, NAV2; as well as transcription and epigenetics 
control related AHR, ARNTL, BACH1, BACH2, BRCA1, 
BRCA2, ETS1, NFE2L2, NFKBIZ, RORA, RUNX2; 
BLM, HAT1, HMGB1, MED4, MET, METRN, METTL1, 
PRRX1, TES (Supplementary Table S1 and S2; Figure 
6A). Likewise some genes within the NRF2 network that 
were markedly expressed and up regulated following 
combination immunotherapy were detoxification and 
metabolism related ABCB9, ABCC1, ABCC10, ACOX2, 
GPX2, GPX4, GSR, GSS, GSTA2, GSTM1, GSTM2, 
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GSTM3, TALDO1, UGT1A6; cell signaling, proliferation, 
inflammation and immunity, and angiogenesis, related 
AKT1, CEBPA, DUSP5, DUSP5P, DUSP6, ERBB2, 
ERBB2IP, ERBB3, FOXA2, FOXJ2, FOXJ2, FOXO1, 
FOXO3, JUN, NFE2L1, PDGFB, RPS6KA2, RPS6KB2; 
cell cycle regulation, cell survival and death related 
CDKN1A, CDKN1B, CDKN2A, CDKN2B, CASP1, 
FRMD6, VAV3; as well as stability, transcription and 
epigenetics control related BACH1, BACH2, BTRC, 
KEAP1, MAFF, MAFG, MAFK, NOTCH1, NOTCH3, 
PRRX2, NCOA6, NCOR1, RARA, RCOR3, RORA, 
RXRA, RXRB, RXRG, SYK, XBP1, HDAC1, HDAC3, 
HDAC5 (Supplementary Table S1 and S2; Figure 6A). 
Some similarly related gene expression changes were seen 
with single immunotherapy, Trastuzumab or Pertuzumab, 
but sometimes to a different magnitude and different 
direction.
It is clear that Trastuzumab, Pertuzumab and 
combination have all produced significant induction of 
KEAP1 expression. Whilst Trastuzumab and Pertuzumab 
caused significant induction of NRF2 expression, their 
combination strikingly resulted in the profound and 
highly significant down regulation of NRF2 expression. 
These in vivo observations strongly supported our in 
vitro data (Figure 5C) regarding the status of NRF2 and 
KEAP1 following immunotherapies. Further analyses and 
visualization of the in vivo gene expression data (Figure 
7 and Figure 8) confirmed our observed perturbations in 
the NRF2 network and down regulation of some NRF2 
target genes, especially genes associated with antioxidant 
responses and glutathione metabolism These give credence 
to our assertion of ROS production and compromise of 
NRF2 status and functions as the basis of action and 
effectiveness of the immunotherapies, especially with 
the combination of Trastuzumab and Pertuzumab. It is 
of interest to observe the up regulation of expression of 
HDACs and certain nuclear co-repressor genes, as well 
as the down regulation of HAT expression and its related 
functional homologues or orthologues such as DNA2, 
HES1, MED4, MET, METRN, METTL1, which point to 
Figure 6: NRF2 network dependent molecular responses to Trastuzumab and Pertuzumab alone or in combination. 
A. Heatmap showing significant (p=0.001) differential expression of genes within the NRF2 network relative to control treatment of 
SKOV3 ovarian xenograft tumors (SAM FDR=10%) as in References [15, 48]. Red represents increased expression and green decreased 
expression relative to the median of the controls. B-D. Volcano-plots showing gene expression changes within the NRF2 network following 
Trastuzumab (B), Pertuzumab (C), and their combination (D) treatment of the SKOV3 xenograft tumors. The genes with significant (p 
≤ 0.05) and non-significant fold changes are colored red and black, respectively, while some genes with a high fold change are marked 
by blue crosses. E-F. Venn diagram showing distinct and overlap of significantly up-regulated (E) and down-regulated (F) transcripts of 
genes within the NRF2 network relative to control treatment of SKOV3 xenograft tumors with Trastuzumab and Pertuzumab alone or in 
combination.
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Figure 7: Common and differential expression changes in transcription and epigenetics associated genes in responses 
to Trastuzumab and Pertuzumab alone or in combination of. A. Heatmap showing differential changes B. Heatmap showing 
significant (p≤0.05) differential changes in the expression of the genes relative to control treatment of SKOV3 ovarian xenograft tumors 
(SAM FDR=10%) as in References [15, 48]. Red represents increased expression and green decreased expression relative to the median of 
the controls. C, D. Volcano-plots showing gene expression changes in transcription and epigenetics associated genes following trastuzumab 
(C), pertuzumab (D), and their combination E. treatment of the SKOV3 xenograft tumors. The genes with significant (p ≤ 0.05) and non-
significant fold changes are colored red and black, respectively, and some genes with a high fold change are marked by blue crosses.
Figure 8: Visualization of common and differential gene expression changes within the NRF2 network and signaling 
pathways. Network of gene expression profiles in response to either Trastuzumab A. or Pertuzumab B. alone, or following their 
combination treatment C. in SKOV3 xenograft tumors from References [15, 48], and as depicted in the NRF2-related interactome and 
regulome model of Papp D et al 2012 [50]. The color of the node depicts the ratio of the expression values with drug compared to the 
expression values in control samples.
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transcriptional packaging and control. Consequently, we 
hypothesized that transcriptional silencing and epigenetics 
may contribute to the distinct mechanisms of inhibition 
of NRF2 function by combination immunotherapy. In 
an attempt to test this hypothesis, we used KEGG and 
knowledge-based approach to examine the in vivo gene 
expression data with particular attention to transcription 
and epigenetics pathways. The data obtained (Figure 8) 
supported this hypothesis, which we later confirmed using 
our in vitro cell models (Figures 9–11). Overall there is 
agreement between the in vitro and the in vivo data.
Combination treatment with Pertuzumab and 
Trastuzumab causes transcriptional repression 
of NRF2 leading to downregulation of expression 
of genes under its regulation
In order to verify the in vivo data of microarray and 
confirm transcriptional inhibition of NRF2 in our own 
cell line models, we adopted two approaches. Firstly, we 
performed quantitative RT-PCR (qRT-PCR) on cDNAs 
obtained from PEO4, OVCAR4 and SKOV3 previously 
exposed to combination treatment of Pertuzumab and 
Trastuzumab for 96 h. In this experiment, we firstly 
quantitatively determined basal expression levels of 
NRF2 and its substrates HO-1 and GCLM through qRT-
PCR (Figure 9A). Consistent with previous reports, we 
found significantly higher basal levels of NRF2 [31] as 
well as HO-1 and GCLM levels in PEO4 than OVCAR4 
and SKOV3, with OVCAR4 having the least expression 
levels. More importantly, following 96 h of treatment 
with combination of Pertuzumab and Trastuzumab, there 
was significant downregulation of NRF2 expression in 
all the three cell lines tested. Furthermore, HO-1 and 
GCLM expression were reduced following the same 
treatments (Figure 9B). This demonstrated and confirmed 
that targeted therapy cause transcriptional repression 
of NRF2 leading to downregulation in expression of its 
transcriptional substrates and as such confirmed the in vivo 
microarray data.
In the second and related strategy, we cloned the 
1.5kb promoter region of NRF2 gene into a luciferase 
reporter vector to generate a luciferase based reporter assay 
for NRF2 transcription (called prNRF2). This reporter was 
Figure 9: qRT PCR analysis of NRF2 and its substrates reveal downregulation of NRF2, HO-1 and GCLM mRNA 
expression following treatment with targeted immunotherapeutic agents. A. Ovarian cancer cell lines exhibit different basal 
levels of NRF2 and its substrate expression. Exponentially growing cells were treated with 1nM Heregulin for 96 h. Following this, cells 
were harvested for total RNA for subsequent reverse transcription to generate cDNA and used to perform quantitative Real Time PCR (qRT 
PCR) as described in Materials and Methods. B. Treatment with combination of Pertuzumab and Trastuzumab causes downregulation of 
NRF2, HO-1 and GCLM mRNA. Cells were exposed to combination of 20μg/mL of Pertuzumab and Trastuzumab for 96 h before being 
harvested for RNA and subjected to qRT PCR as in (A). C. Luciferase reporter assay for NRF2 transcription demonstrates repression of 
NRF2 transcription following exposure to HER2 targeting immunotherapeutic agents. Exponentially growing PEO4 and SKOV3 cells 
were transfected with either empty PGL3 basic vector or 1μg PGL3 basic vector with cloned 1.5kb fragment of NRF2 promoter (prNRF2) 
driving the expression of luciferase gene. Co-transfection with 0.2μg pRL-CMV plasmid was performed as an internal transfection control 
as described in the Materials and Methods. At 24 h post-transfection, cells were either left untreated in media containing 1nM HRG (UT) or 
treated with combination of 20μg/mL of Pertuzumab and Trastuzumab (COMB) for 96 h. Following treatments, cell lysates were prepared 
from the transfected cells, transferred to opaque flat bottom white 96-well plates and their luciferase activity recorded using Dual luciferase 
reporter assay (Promega) in multiplate luminometer (MODULUS™, Promega). For (A), (B) and (C), data are means with ± S.D of triplicates 
and expressed as fold change with statistical significance determined by either ONE WAY ANOVA or independent t test as appropriate 
according to the scale * P <0.05, **P <0.01, ***P <0.001.
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Figure 10: Treatment with HER2 targeting immunotherapeutic agents causes induction of HDAC1 expression and 
repression in phospho-HDAC levels. A. Immunoblotting analysis showing induction of total HDAC 1 levels following treatment 
with combination of Pertuzumab and Trastuzumab in PEO4, OVCAR4 and SKOV3 cell lines. Exponentially growing cells were either 
left untreated (UT) or treated with media containing 1nM Heregulin alone (HRG), or with co-treatment of 20μg/mL of Pertuzumab (PR), 
Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested for immunoblotting using an anti-HDAC1 antibody (Table 
1). Ponceau stain of the same blot was used as loading control Red bars indicate HDAC1 levels following quantification of the immunoblot 
signal intensities obtained and normalized to the value of UT and expressed as fold change. The signal intensities of bands were quantified 
as described in Materials and Methods, B. Treatment with HER2 inhibitors causes induction of nuclear HDAC1 levels. Immunofluorescent 
labelling of endogenous HDAC1 in cells previously grown on poly-L lysine coated coverslips and exposed to treatments as in (A). For 
immunolabelling, Alexa Fluor® 568 conjugated secondary antibody (red fluorescence) was used. Nuclear reference was provided by co-
staining with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica DMiRe2 electronic microscope 
using integrated features of ANDOR iQ core software (ANDOR Technologies Ltd). Scale bar indicates 10μm. These are representative 
images taken in different field of views with relevant fluorescence channels and 100x objective. C. Immunoblotting analysis of phospho-
HDAC levels following treatment with combination of Pertuzumab and Trastuzumab in PEO4, OVCAR4 and SKOV3 cell lines. 
Exponentially growing cells were either left untreated (UT) or treated with media containing 1nM Heregulin alone (HRG), or with co-
treatment of 20μg/mL of Pertuzumab (PR), Trastuzumab (TR) or their combination (COMB) for 96 h before being harvested to prepare 
protein lysates and processed for immunoblotting using an anti-phospho HDAC antibody (Table 1). Ponceau stain of the same blot was 
used as loading control (not shown). Red bars indicate phospho-HDAC levels following quantification of the immunoblot signal intensities 
obtained in (A) and normalized to the value of UT and expressed as fold change. The signal intensities of bands were quantified through 
integrated optical densitometry measurement as described in Materials and Methods.
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used to directly report any transcriptional perturbation of 
NRF2. We transfected prNRF2 into our ovarian cancer 
cell lines, repeated the immunotherapeutic combination 
treatment for 96 h and assayed cells for luciferase activity 
(Figure 9C). We found that indeed combination treatment 
significantly reduced luciferase signal, demonstrating 
transcriptional inhibition of NRF2 expression in both 
PEO4 and SKOV3 cell lines. In this transient transfection 
strategy, by 96 h, we could not obtain any detectable 
expression of our vectors in OVCAR4 (data not shown). 
These experiments clearly demonstrated transcriptional 
inhibition of NRF2 and explain the repression of NRF2 
protein seen before (Figure 5C).
HER2 targeting immunotherapeutic agents 
cause upregulation of HDAC1 and repression 
of phospho HDAC levels demonstrating HDAC 
activation
A noticeable feature in our in vivo microarray 
data analysis was the finding that several histone 
deacetylases (HDACs) levels were upregulated (Figure 
7). Upregulation and activation of HDAC1 would lead 
to diminished acetylation, increased methylation and 
subsequent repression of gene expression [66, 67]. We next 
sought to determine whether upregulated HDAC1 could 
be reproduced in our cell lines following combination 
treatment in vitro, which could further serve to explain 
the transcriptional downregulation of NRF2 expression 
during such treatments. Firstly, we immunoblotted for 
total HDAC1 in our three cell lines and saw induction of 
HDAC1 only in combination treatment, albeit to different 
levels in each cell line (Figure 10A). Furthermore, we 
fluorescently immunostained total HDAC1 and confirmed 
nuclear upregulation following combination treatment 
(Figure 10B). We next examined phosphorylated levels 
of HDAC4 (Figure 5 and Figure 7). Phosphorylation of 
HDAC was previously shown to repress its activity by 
nuclear export [68, 69]. We found a clear repression of 
phospho-HDAC following combination treatment for 96 
h in PEO4 and OVCAR4 cell line. However, in SKOV3, 
we could not see such repression (Figure 10C).
Inhibition of HDAC and DNA methyl 
transferases induce NRF2, HO-1 and 
transcriptional antioxidant response, and disrupt 
immunotherapy dependent repression of NRF2
While the diminished levels of NRF2 protein seen 
earlier could be partly explained by induction of KEAP1 
during some treatments, the same does not explain its 
transcriptional repression. Upregulation of HDAC1 as 
seen in Figure 10 on the other hand warrants itself for 
further study, as this could be a potential mechanism of 
transcriptional repression of NRF2, especially upon the 
finding of HDAC1 induction following combination 
treatment.
For these reasons, we next tested this assumption 
by repeating exposure of our cells to the combination of 
Pertuzumab and Trastuzumab, but also treating cells with 
combination of inhibitors of HDAC1, Trichostatin (TSA) 
or that of DNA methylation, namely 5-azacytidine (5-Aza) 
[70, 71], collectively called T/A. Both these inhibitors are 
expected to relief transcriptional inhibition of genes that 
are under epigenetic regulation and silenced by DNA 
methylation dependent mechanisms. We found that not 
only did T/A lead to NRF2 induction, suggesting relief of 
methylation dependent suppression of its gene expression, 
but more importantly, it also disrupted the inhibitory 
action of 96 h of HER2 inhibitors treatments (Figure 11A). 
Table 1: Antibodies used in the study
Antibody Host Catalogue Number Company
NRF2 Rabbit Sc-722 Santa Cruz
KEAP1 Rabbit 4678S Cell signalling
Phospho Her2 T877 Rabbit 2241S Cell signalling
Phospho AKT 473 Rabbit 4060S Cell signalling
HDAC1 Mouse 5356 Cell signalling
PhosphoHDAC Rabbit 3443 Cell signalling
Heme Oxygenase 1 (HO-1) Rabbit sc-10789 Santacruz
Alexa fluor 488 conjugated 
secondary antibody Rabbit ab150077 Abcam
Alexa fluor 568 conjugated 
secondary antibody Rabbit ab175471 Abcam
β-actin Rabbit ab1801 Abcam
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We could also show such T/A dependent induction of both 
NRF2 and its downstream transcriptional target, HO-1 at 
single cell level by performing immunostaining (Figure 
11B). This important finding firstly demonstrated that 
NRF2 gene expression could be subjected to epigenetic 
regulation involving DNA methylation and/or acetylation; 
secondly, that the inhibition of NRF2 following exposure 
to HER2 targeting drugs involves the above mechanism; 
thirdly that as such, this could be disrupted by using 
specific inhibitors also leading to induction of NRF2 
Figure 11: Inhibition of HDAC and DNA Methyl Transferase induce NRF2 protein levels, causes nuclear localization 
of NRF2 and HO-1, disrupts both targeted immunotherapy dependent NRF2 protein and transcriptional repression, 
and activates NRF2 dependent antioxidant transcriptional response program. A. Immunoblotting analysis showing induction 
of total NRF2 levels following treatment with combination of Trichostatin and 5-azacytidine both in the absence and presence of HER2 
inhibitors. Exponentially growing cells were either left untreated in media containing 1nM Heregulin alone (UT) or treated with either 
a combination of 20μg/mL Pertuzumab and Trastuzumab (COMB), with combination of 200nM Trichostatin A and 2μM 5-Azacytidine 
(T/A) or with all four drugs together for 96 h. Following incubation, cells were harvested to prepare protein lysates and processed for 
immunoblotting using relevant antibodies (Table 1). Blotting with β-actin was used as loading control. Red bars indicate NRF2 levels 
following quantification of the immunoblot signal intensities obtained in (A) and normalized to the value of UT and expressed as fold 
change. The signal intensities of bands were quantified through integrated optical densitometry measurement using Gelpro software 
(Version 3.1, Media Cybernetics). B. Treatment with T/A causes nuclear induction of NRF2 and HO-1 levels. Immunofluorescent labelling 
of endogenous NRF2 (upper panels) and HO-1 (lower panels) in cells previously grown on poly-L lysine coated coverslips and exposed 
to T/A treatments as in (A). For immunolabelling, Alexa Fluor® 488 conjugated secondary antibody was used for NRF2 staining (green 
fluorescence), while Alexa Fluor® 568 conjugated secondary antibody was used for HO-1 staining (red fluorescence). Nuclear reference 
was provided by co-staining with 4',6-Diamidino-2-Phenylindole, Dihydrochloride (DAPI). Images were captured with Leica DMiRe2 
electronic microscope, while merging, co-localization and further analysis were performed by using integrated features of ANDOR iQ 
core software (ANDOR Technologies Ltd). Scale bar indicates 10μm. These are representative images taken in different field of views 
with relevant fluorescence channels and 100x objective. C. Inhibition of HDAC and DNA Methyl Transferase disrupt the transcriptional 
inhibition of NRF2 exerted by the HER2 targeting immunotherapeutic agents. Exponentially growing PEO1 and SKOV3 cells were 
seeded in triplicates in 24 well plates and transfected with either empty PGL3 basic vector or 1μg PGL3 basic vector with cloned 1.5kb 
fragment of NRF2 promoter (prNRF2) driving the expression of luciferase gene. Co-transfection with 0.2μg pRL-CMV plasmid was 
performed as an internal transfection control. At 24 h post-transfection, cells were either left untreated in media containing 1nM HRG (UT) 
or treated with combination of 20μg/mL of Pertuzumab and Trastuzumab (COMB), or combination of 200nM Trichostatin A and 2μM 
5-Azacytidine (T/A) or combination of COMB and T/A as indicated for 96 h. Following treatments, cell lysates were prepared from the 
transfected cells, transferred to opaque flat bottom white 96-well plates and their luciferase activity recorded using Dual luciferase reporter 
assay (Promega) in multiplate luminometer (MODULUS™, Promega). D. Inhibition of HDAC1 and DNA Methyl Transferases induce 
NRF2 dependent antioxidant transcriptional program. Exponentially growing AREc32 cell line stably expressing NRF2 dependent 8xcis- 
regulatory antioxidant response elements were seeded in triplicates in opaque 96 well plates and either mock treated (DMSO) or exposed 
individually to either 50μM tert-butylhydroquinone (tBHQ), 5μM Sulforophane (Sul), 5μM Trichostatin (TSA), 5μM 5-azacytidine (5-
Aza), or a combination of tBHQ with either TSA or 5-Aza, or a combination of Sul with TSA or 5-Aza for 24 h. Following this, cell lysates 
were prepared and assayed for Luciferase activity (BrightGlo Luciferase system, Promega). For (C) and (D), Data are the means with ± S.D 
of triplicates and expressed as fold change with statistical significance determined by ONE WAY ANOVA followed by Tukey’s post hoc 
test according to the scale * P <0.05, **P <0.01, ***P <0.001.
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substrates. We next made use of AREc32 cell line, the 
stable clone of antioxidant response reporter to further 
study the consequences of HDAC1 and DNA methylation 
inhibition on NRF2 dependent antioxidant response 
pathway. In this strategy, we used TSA and 5-Aza either 
alone or with classical activators of NRF2 to see whether 
that would lead to further antioxidant activation. While the 
classical NRF2 activator, tert-butylhydroquinone (tBHQ) 
and sulforophane induced ARE signal by 13 and 2.5 fold 
respectively, TSA alone led to almost 35-fold induction 
(Figure 11C). Furthermore, TSA could further enhance 
ARE signal in tBHQ treated cells to more than 70 fold. 
These findings further validated our earlier assumption of 
the involvement of epigenetic mechanisms in regulating 
NRF2 and hence its downstream antioxidant pathway.
To further confirm the transcriptional mechanism 
of NRF2 regulation following T/A treatments, we used 
prNRF2, our cloned NRF2 luciferase based promoter 
assay as its transcriptional reporter. We found that while 
combination treatment of Pertuzumab and Trastuzumab 
repressed NRF2 transcription, cotreatment with T/A 
disrupted this repression in both PEO4 and SKOV3 cell 
line with the latter showing a more pronounced induction 
of NRF2 transcription following T/A cotreatment 
(Figure 11D).
Altogether, findings in this set of experiments 
demonstrate the involvement of transcriptional and 
epigenetic mechanisms of NRF2 regulation with its effects 
seen both at the transcriptional, single cell and overall 
protein levels.
Anti HER2 targeted therapy causes NRF2 
promoter methylation explaining its 
transcriptional repression following HER2 
inhibition
In order to more directly determine the epigenetic 
basis of NRF2 regulation following combination of HER2 
targeting drugs, we performed epigenetic study of NRF2 
promoter involving methylation profiling. This was also 
done to explain the transcriptional and protein induction 
of NRF2 followed by activation of its antioxidant function 
upon inhibition of HDAC and DNA methylation. To do 
this, we first performed in silico analysis of the NRF2 
promoter to identify CpG islands (Supplementary Figure 
S1A). This was done using the CpG analysis program 
Methprimer (http://www.urogene.org/methprimer/). 
This analysis identified a CpG island containing 18 CpG 
dinucleotides (Figure 12C and Supplementary Figure 
S3A). We next designed primers specific for amplification 
of bisulfite converted DNA but not unconverted DNA, 
exposed all three cell line models of this study to 96 h 
of Pertuzumab and Trastuzumab combination treatment, 
isolated total genomic DNA from exposed cells and 
Figure 12: Combination of HER2 targeting immunotherapeutic agents, Pertuzumab and Trastuzumab cause 
hypermethylation of NRF2 promoter. Exponentially growing PEO4, OVCAR4 and SKOV3 cell lines were seeded in 60mm tissue 
culture plates and either left untreated in media containing 1nM HRG, or treated either individually or in combination with 20μg/mL of 
Pertuzumab and Trastuzumab for 96 h. Following this, cells were harvested for total genomic DNA, bisulfite converted, quantified and 
subjected to PCR using specific primers flanking the predicted CpG methylation sites in NRF2 promoter. PCR products were sequenced, 
analyzed and examined for conserved CpG dinucleotides indicating methylation.
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performed its bisulfite conversion. Such conversion 
converted all the non-methylated cytosine nucleotides in 
the DNA to Thymine, whereas the methylated cytosines 
being resistant to such conversion remained intact. Using 
the designed bisulfite conversion specific primers flanking 
the predicted CpG island, we set up PCR, amplified 
this region, purified and sequenced it (Supplementary 
Figure S3). Careful analysis of the sequencing results 
revealed striking differences in the sequences between 
untreated and treated cell lines (Table 2). We found that 
only one CpG dinucleotide among the 18 predicted was 
methylated in the PEO4 cell line in the untreated state 
(CpG dinucleotide at position 206, Figure 11C). However, 
following treatments, we found a total of six CpG 
dinucleotides retained following conversion, suggesting 
their methylation (CpG dinucleotides at positions 43, 79, 
159, 163, 184 and 206, Figure 11C). OVCAR4, which 
showed the least inhibition of NRF2 protein following 
drug treatment also exhibited limited CpG methylation 
with only three CpG dinucleotides showing methylation 
(position 138, 184 and 245). A surprising finding was with 
SKOV3, which only exhibited a single conservation of the 
CpG dinucleotide, suggesting a single methylated cytosine 
at position 157 (Figure 12C). The disparity between a very 
pronounced NRF2 protein inhibition in SKOV3 (Figure 
5C) while still very limited methylation profile could be 
explained by the fact that KEAP1 induction during the 
same treatments was the highest in this cell line potentially 
accounting for this as a contributing factor in NRF2 
repression.
This is the first report of NRF2 promoter methylation 
profiling following HER2 targeted immunotherapy. This 
novel finding demonstrated for the first time that the 
human NRF2 promoter in three ovarian cancer cell lines 
exhibited methylation following combination treatment 
and hence identifies a novel mechanism of transcriptional 
repression of NRF2.
DISCUSSION
The introduction of monoclonal antibody based 
targeted anticancer immunotherapy in the form of HER2 
targeting Trastuzumab (Herceptin) and Pertuzumab has 
opened a new chapter in cancer immunotherapeutics. 
It has significantly improved our understanding of the 
biology of HER2-related cancers and the emergence of 
novel anti-HER2 drugs for the treatment of cancers. While 
several mechanisms, including inhibition of proliferation 
and angiogenesis, DNA repair and extracellular domain 
cleavage for recruiting host immune natural killer 
(NK) cells and triggering of an antibody-dependent 
cell-mediated cytotoxicity (ADCC) process [75] have 
been identified for Trastuzumab, the mechanism of 
action of Pertuzumab has appeared limited to primarily 
inhibiting signal transduction by blocking the function of 
HER2. Several in vitro and in vivo studies have clearly 
elucidated this mechanism of action by Pertuzumab 
[76–79]. Although these therapies work by different 
mechanisms, it appears that to exert an antitumor effect, 
they should for example inhibit phosphorylation of HER3 
and antagonise the PI3K/AKT pathway [25, 28, 29]. 
Detailed experimental and clinical studies have shown the 
complimentary and enhanced efficacy and safe tolerability 
of HER2 targeting and blockade by the novel combination 
of Trastuzumab with Pertuzumab [32, 80–84]. However, 
treatment outcomes with single agent or combination of 
agents remain fairly unpredictable, tumour type specific 
and tumour biology dependent, especially the expression 
levels of cell surface receptors, their dimerization 
preferences, recycling kinetics and ligand abundance [25, 
33–35, 85]. Also the molecular mechanisms responsible 
for susceptibility and de novo and/or acquired resistance 
to these HER2 targeted immunotherapeutic agents are 
poorly understood. In this study we aimed to identify and 
characterise novel signalling pathways that might explain 
the efficacy of HER2-targeted immunotherapies that are 
critical to avoid or to overcome resistance.
In the current study, we sought to determine the 
mechanism of action of targeted immunotherapeutic 
agents and in particular to understand the enhanced 
cytotoxic response triggered uniquely by combination 
of immunotherapeutics rather than individual agents. We 
determined the degree of sensitivity of ovarian cancer 
cells derived from different origins to the HER2 targeting 
antibodies, Pertuzumab and Trastuzumab, either employed 
alone or in combination. These ovarian cancer cell lines are 
of low (OVCAR4), moderate (PEO4), and high (SKOV3) 
HER2 expression status [34], in addition to having 
Table 2: Conserved CpG dinucleotides demonstrating methylated cytosines
Cell Line
Conserved CpG dinucleotides
UT Position Treated Position *
PEO4 1 206 6 46, 79, 159, 163, 184, 206
OVCAR4 0 - 3 138, 184, 206
SKOV3 0 - 1 157
* Nucleotide position within the 270bp CpG island in NRF2 promoter (see Supplementary Figure S3).
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variable expression levels of HER3, the key dimerization 
partner of HER2 in the order PEO4>OVCAR4>SKOV3 
[34]., We found that at least part of mechanism of action 
of the HER2 targeted immunotherapeutic agents involved 
generation of ROS, which contributed to the killing 
effects and cancer growth retardation. This is consistent 
with the conventional adage that depletion of GSH can 
cause oxidative stress and sensitise tumours to the killing 
effects of the therapeutic agents. These observations were 
further reinforced by the use of NAC to attenuate ROS 
and desensitise, or of RA to elevate ROS, and augment the 
cytotoxicity of Trastuzumab and Pertuzumab.
The cell lines exhibited complex and different 
degrees of cytotoxicity to Pertuzumab and Trastuzumab 
alone or their combination. However, the combination 
treatments produced the greatest cytotoxicity and killing 
effect, as well as the highest inhibition of RTK signalling, 
consistent with previous observations [25, 32, 33]. Since 
we have recently characterised these cell lines as having 
different levels of NRF2, KEAP1, hierarchical addiction 
to ROS and its potential for manipulation, intricate with 
their proliferative capacity [10, 11], we postulated any or 
all of these to be possibilities for the observed differential 
response to the different immunotherapies, especially 
the combination therapy. The rationale for this postulate 
was the fact that RTK and AR pathways share common 
substrates, both pathways are cytoprotective and pro-
survival in nature and both these have been implicated in 
drug resistance. Additionally, recent studies have explored 
and identified co-modulatory and co-regulatory roles of 
the two pathways [36–39].
Interestingly, combination of the targeted 
immunotherapeutic agents (Pertuzumab and Trastuzumab) 
caused down regulation of NRF2, induction of KEAP1, 
and depletion of glutathione, features that were ascribable 
to inhibition of the NRF2 dependent antioxidant 
transcriptional program. These demonstrated that HER2 
targeting monoclonal antibodies repress the NRF2 
dependent antioxidant pathway, which may contribute 
to the enhanced cytotoxicity for the combination of 
Pertuzumab and Trastuzumab.
Next, we sought evidence that the mechanism 
of action and effectiveness of HER2 targeted 
immunotherapies, in particular the combination of 
Trastuzumab and Pertuzumab, in vivo, is characterised by 
inhibition of NRF2 function. We did this by performing a 
series of in vitro experimentation, as well as bioinformatic 
analysis of microarray data from the in vivo SKOV3 
xenograft model of HER2 targeting immunotherapies 
[32] as before [25]. In our analysis of gene expression we 
focused on the NRF2 network using a knowledge-based 
approach that was informed by previous reports [50–54]. 
Firstly, we demonstrated that the suppressive effects of 
combination therapy on the AR pathway seen in vitro 
(Figure 1 and Figure 2) were reproduced in vivo (Figure 
6–8). Significant changes in the gene expression of NRF2 
and the NRF2 network signalling were observed following 
treatment with anti-HER2 immunotherapies in the SKOV3 
xenograft. The most dynamic effects and changes were 
seen with the combination therapy. Up regulation of some 
of the genes within the NRF2 network can be explained 
by the takeover of transcriptional control of such genes 
by other significantly induced transcription factors like 
the FOXO family and NFE2L1 (NRF1). Thus the in vivo 
model supported and confirmed the results of our in vitro 
model, which showed that the effectiveness of HER2-
target immunotherapy is greatly and significantly informed 
by repression of NRF2 and its antioxidant function. A 
number of classical NRF2-dependent genes like AKR1C1, 
ATP1B1, BRCA1, BRCA2, GAPDH, GCLM, GCSH, 
GSTM4, H6PD, HMOX1, IDH1, NQO1, PRDX1, SOAT1, 
SOD2, UGDH TUBB3, and VEGFA were suppressed, 
especially with combination therapy.
Several possible mechanisms of NRF2 inhibition 
seen in vitro and in vivo could be identified and explained 
from the microarray analyses. First, the classical NRF2 
and KEAP1 relationship, levels and dynamics appeared to 
be in place following the HER2 target immunotherapies in 
vivo as observed with the in vitro model. The expression 
of NRF2 significantly decreased following combination 
treatment. This supports the notion that NRF2 opposes 
the action and effectiveness of Trastuzumab and 
Pertuzumab, perhaps by promoting the sequestration of 
the ROS generated to kill cells following immunogenic 
drugs administration. Further, this notion is strengthened 
and supported by the observation that the expression of 
KEAP1 was significantly induced following both single 
and combination treatments with least induction observed 
under combination treatments. However, the ratio of 
NRF2/KEAP1 expression was higher under single agent 
than with combination treatments, suggesting greater 
degradation and inhibition of NRF2 function [7, 8] with 
combination than with single agents.
The mechanisms by which retinoic acid (RA) 
inhibits NRF2 and its function are known [62, 86] and 
have been the basis for our use of RA to modulate cellular 
NRF2 status, ARE-dependent transcriptional program and 
to implicate NRF2 in regulating cellular susceptibility to 
HER2 targeted immunotherapies. Interestingly, we found 
increased expression of RXR and RARA genes following 
Trastuzumab, Pertuzumab, and their combination treatment 
of the SKOV3 xenograft tumours. This suggested that 
these mechanisms may play a part in vivo to inhibit NRF2 
function and thus influence the effectiveness of the HER2 
target immunotherapies. Also GSK3 expression appeared 
stable and the expression of FYN kinase was induced, by 
all the immunotherapies against the SKOV3 xenograft 
tumours, especially with combination therapy where the 
expression of β-TrCP was induced, which highlights 
another possible mechanism of controlling NRF2 
levels and functions [87–89]. Further, the down and up 
regulation of BACH1 and BACH2 expression following 
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single agent and combination therapy, respectively, could 
help explain the greater loss of NRF2 function in the 
combination therapy, since BACH is a negative regulator 
of ARE-NRF2-dependent transcription of genes [90–92]. 
Moreover, there was up regulation of expression of MAF 
gene family (MAFF, MAFG, MAFK), especially following 
combination therapy, an observation that agrees with the 
notion of the negative regulation of ARE-NRF2 dependent 
transcriptional program [93, 94].
Further analyses and visualisation of the in vivo 
gene expression data confirmed perturbations in the 
NRF2 network and down regulation of some NRF2 
target genes, especially genes associated with antioxidant 
responses (AKR1B1, AKR1C1, HMOX1, NQO1, FRMD6, 
GAPDH, IDH1, PRDX1, SOAT1, SOD2) and glutathione 
metabolism (ATP1B1, ATP2A1, GCLM, GCSH, GSTM4, 
H6PD). These supported the role of ROS production and 
the undermining of NRF2 status and functions as the 
bases of action and effectiveness of the immunotherapies, 
especially with the combination of Trastuzumab and 
Pertuzumab. It is pertinent to describe the up regulation of 
expression of HDACs (HDAC1, HDAC3, HDAC5, SIRT7), 
histone methyl transferases with CpG binding protein 
(CXXC1) and certain nuclear co-repressor genes (NCOA6, 
NCOR1, PRC1, RCOR3), as well as the down regulation 
of expression HAT and its related functional homologues 
or orthologues like DNA2, HES1, MED4, MET, METRN, 
METTL1. These observations highlighted genetic and 
transcriptional packaging, suturing and control, which 
consequently led us to hypothesise that transcriptional 
silencing and epigenetics, as shown before [95, 96] may 
contribute to the distinct mechanisms of inhibition of 
NRF2 function by combination immunotherapy. These 
data and those from the NRF2 gene promoter methylation, 
transcriptional assays and HDACs dynamics using our 
in vitro cell models supported the hypothesis. Overall 
there is agreement between the in vitro and the in vivo 
data which together illustrate the important role of NRF2 
in influencing outcomes to targeted therapies involving 
HER2 receptor inhibition. Moreover, our recent work on 
the regulation of HER2 and HER3 by NRF2 to oppose 
HER2 targeted immunotherapy [45], gives further support 
and credence to this assertion. The study has also opened 
up a new potential avenue of improving the effectiveness 
of Trastuzumab (Herceptin), which currently benefits 
less than 30% of breast cancer bearing patients and as 
Trastuzumab-associated chemotherapy can modulate the 
pro-inflammatory markers of HER2-positive breast cancer 
patients [97].
CONCLUSION
We have elucidated a novel mechanism of 
action for the combination of HER2 target anticancer 
immunotherapeutic agents. We demonstrate that 
combination treatment with HER2 targeting monoclonal 
antibodies Pertuzumab and Trastuzumab cause greater 
inhibition of NRF2 function and subsequent greater 
repression of NRF2 dependent antioxidant responses in 
human ovarian cancer cell lines. The degree of repression 
of NRF2 determines the overall sensitivity of cancer cells 
towards the HER2 targeted therapies, an axis that could 
be modulated to further sensitise otherwise resistant 
ovarian cancer cells. Furthermore, we present evidence 
that methylation leading to transcriptional repression 
and gene silencing at the NRF2 promoter occurs 
following combination of Pertuzumab and Trastuzumab 
treatments. Therefore the greater effectiveness and 
enhanced cytotoxic action of the combination of the 
HER2 targeted immunotherapeutic agents may be 
at least partially explained by their unique ability to 
cause transcriptional inhibition of NRF2 and greater 
repression of its antioxidant function in low, moderate 
and high HER2 expressing ovarian cancer cell lines. 
This study expands the role of NRF2 as a key element 
in driving drug resistance and opens up a novel strategy 
of sensitising cancer cells to HER2 targeted therapy, as 
well as overcoming the resistance of cancer cells to such 
immunotherapeutics.
MATERIALS AND METHODS
Cell lines, culture conditions and treatments
Human ovarian cancer cell lines PEO4, OVCAR4 
and SKOV3 were maintained in RPMI 1640 media 
(Gibco® Invitrogen) supplemented with 10% foetal 
bovine serum (FBS), 2 mM glutamine, 1 mM sodium 
pyruvate, 100 μg/ml streptomycin and 100 U/ml penicillin 
in an atmosphere of 5% CO2 and incubated at 37°C. 
Before experimental treatments, cells were grown for 24 
h in RPMI 1640 media prepared as above but replacing 
FBS with 5% double charcoal stripped FBS (Fisher). 
Heregulin-β1 (HRG, Sigma) was used by preparing 1 
μM stock solution made with 5% trehalose, 10% FBS 
in PBS and diluted to a final concentration of 1nM 
with media during treatments. Monoclonal antibodies 
targeting HER2 receptor, Pertuzumab and Trastuzumab 
or their combinations were used by directly diluting the 
drugs in media to a final concentration of 20 μg/mL. 
For Retinoic acid (RA) treatments, a stock solution of 
40 mM was made in 100% ethanol in amber Eppendorf 
tubes pre-aired with nitrogen gas. Once the stock 
solution was made, it was bubbled again with nitrogen 
gas and closed, stored at -80°C and protected from light 
until further use. A final concentration of 2.5 μM was 
used for treatments. For reducing conditions, 100 mM 
N-Acetyl Cysteine (NAC, Sigma-Aldrich) was prepared 
in deionised water and diluted to a final concentration 
of 10 mM with media during treatments. For ROS 
detection, 2′,7′-Dichlorofluorescin diacetate(DCFDA, 
Sigma) solution was prepared with Dimethylsulfoxide 
Oncotarget20www.impactjournals.com/oncotarget
in amber tubes to a concentration of 50 mM and stored 
at -20°C in dark until used. For cytotoxicity assay, 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT) was used by making a stock solution 
of 5 mg/mL in PBS and filter sterilising it. The solution 
was stored at 4°C in the dark until used. To inhibit 
DNA methylation, 5-azacytidine and HDAC inhibitor 
Trichostatin A (collectively referred to as T/A) were used 
at final concentration of 2 μM and 200 nM respectively. 
Mock treatments with DMSO were performed in parallel.
Reactive oxygen species (ROS) detection
The ROS detection assay was performed by using 
2′,7′-Dichlorofluorescin diacetate (DCFDA) staining 
(Sigma). Briefly, cells were seeded in triplicate at a 
density of 5×103 cells/well in opaque flat bottom 96-
well tissue culture plates in 100μl media without phenol 
red and allowed to grow for 24 h before being exposed 
to different treatments. Following required treatments, 
a 50mM stock solution of DCFDA was added to each 
well containing 100 μL pre-existing media to achieve a 
final concentration of 25 μM and incubated for 45 min 
at 37°C. Fluorescence signal intensities indicating ROS 
levels were recorded by taking readings using 96-well 
fluorescent multi plate reader (MODULUSTM, Promega) 
using excitation and emission spectra of 485/535 nm. To 
normalise the fluorescence signal, cells in the same wells 
were subsequently stained with coomassie brilliant blue 
stain (Sigma-Aldrich) for 1 h, washed with distilled water 
and 10% SDS solution added to release the absorbed dye 
for 10 min while shaking. The absorbance values at 595 
nm were then recorded using multiplate absorbance reader 
(MODULUSTM, Promega) and data used to normalise the 
fluorescence values.
Protein extraction and immunoblotting
For immunoblotting, cells were seeded in 60mm 
tissue culture plates and grown until 70% confluent and 
exposed to required treatments. At protein harvest, cells 
were trypsinized (Gibco® Invitrogen), washed with 
PBS, and harvested to obtain protein lysates using RIPA 
buffer (Pierce Biotech) supplemented with protease and 
phosphatase inhibitor cocktail (Pierce Biotech). The 
lysates were subjected to sonication of 2 cycles for 10 
s at 50% pulse. The final mixture was shaken gently on 
ice for 15 min and the protein supernatant was obtained 
following centrifugation of the lysates at 14000 x g for 15 
min. Proteins obtained were quantified by Bradford assay 
(Sigma-Aldrich) using BSA as a standard and sample 
buffer (Nupage LDS, Invitrogen) was added to protein 
lysates, heated at 70°C for 20 min and stored at -20°C until 
further use. On the day of immunoblotting, lysates were 
loaded into wells of 4-12% gradient SDS-polyacrylamide 
gels (Nupage® Bis-Tris gels, Life Technologies) and 
subjected to electrophoresis at 200V for 1-2 h. Following 
this, proteins were transferred to polyvinylidene 
difluoride membranes (GE Amersham) using the XCell 
SureLock Mini-Cell system (Invitrogen) at 50V for 
90 min and processed using a commercially available 
kit (WesternBreeze™ Chromogenic Immunodetection 
Kit, Invitrogen). Non-specific reactivity was blocked 
by incubation with the blocking reagent supplied in the 
kit. Membranes were further treated by incubating with 
primary antibodies (Table 1) for 2 h at room temperature 
or overnight at 4°C, followed by incubation for 30 min at 
room temperature with appropriate secondary anti rabbit 
antibody supplied in the kit. Bands were visualized with 
the BCIP/NBT based chromogenic substrate. For loading 
control, either immunoblotting of the same lysates was 
performed using β-Actin antibody (Abcam Bioscience, 
UK) or the PVDF membranes with transferred proteins 
visualized using Ponceau stain (Sigma).
Cloning and expression vector
The 1.5kb proximal promoter region of NRF2 
upstream of its translational start site was cloned into a 
luciferase reporter vector (Promega) and used to study 
the transcriptional regulation of NRF2. Table 3 lists the 
primers for the amplification of the NRF2 promoter. 
Table 3: Primer sequences
Primers Sequence
Biseq forward 5- TGAGATAAAAGTAGGGTAAGGTTTTGTA-3
Biseq reverse 5- ACTACCAACTAAAATCCCAACAAAC-3
prNRF2 forward 5- CTC GAG GGC GTT GAT TGC TAT AGT CAG G-3
prNRF2 reverse 5- CCA TGG GAT GAG CTG TGG ACC GTG TG-3
GCLC F forward 5-TCTCTAATAAAGAGATGAGCAACATGC-3
GCLC R reverse 5-TTGACGATAGATAAAGAGATCTACGAA-3
Probe 5FAM-CAGGAGATGATCAATGCCTTCCTGCAAC-3BHQ
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Total genomic DNA was isolated from human cells using 
DNeasy Blood and tissue kit (Qiagen) and quantified using 
AstraGene microvolume spectrophotometer (AstraNet). 
100ng of the genomic DNA was used to amplify the 
promoter sequences with MyFi mix (Bioline), using 
primers that incorporated XhoI and NcoI restriction 
endonuclease sites 5’ and 3’ ends of the amplified NRF2 
promoter respectively. PCR conditions for promoter 
amplification were initial denaturation of 95°C for 7 min 
followed by 35 cycles of 95°C for 30 s for denaturation, 
a gradient annealing temperature of 50−60°C for 30 s 
and 72°C for 90 s for extension and a final extension for 
10 min at 72 °C. The PCR products were subjected to 
electrophoresis and extracted from agarose gel (Qiagen), 
digested using XhoI and NcoI restriction enzymes 
(Promega) and ligated into pGL3 basic luciferase vector 
(Promega) to create the NRF2 promoter construct 
(prNRF2) driving the expression of Luciferase gene for 
utilization in a Dual luciferase reporter assay (Promega). 
The integrity of cloned sequences was determined by 
commercial sequencing service (www.dnaseq.ac.uk). The 
NRF2 promoter construct was transfected into relevant 
cell lines using Lipofectamine® 3000 (Life Technologies) 
as a transfection reagent.
Luciferase reporter assay
For the analysis of promoter activities and 
transcriptional regulation of NRF2, the 1.5 kb promoter 
region of NRF2 gene cloned in pGL3 basic vector 
(Promega) was transfected into relevant cell lines. Briefly, 
cells were seeded in triplicates in 24-well plates at a 
density of 2 × 105cells per well and allowed to attach for 
24 h. Following this, cells were either transfected with 1 
μg of empty pGL3 basic vector (Promega) or PGL3 basic 
vector with cloned fragments of NRF2 promoter driving 
the expression of luciferase gene, using transfection 
reagent Lipofectamine 3000® according to manufacturer’s 
instructions (Life Technologies). Co-transfection was also 
performed with 0.2 μg of pRL-CMV vector (Promega) 
expressing renilla luciferase to provide an internal control 
of transfection. Following this, cells were allowed to 
grow for 24 h, subjected to desired treatments, lysed and 
protein lysates transferred to opaque white bottom 96-well 
plates. The dual luciferase activity of fire fly luciferase 
(from cloned promoters) and Renilla (internal control) 
in the harvested lysates was measured sequentially 
by following manufacturer’s instructions (Promega) 
and taking luminescence readings in a luminometer 
(MODULUSTM, Promega). To determine the NRF2 
dependent transcriptional antioxidant response following 
different treatments, stable clones of MCF7 cells carrying 
pGL3 vector with a cloned 8 copies of Cis-Antioxidant 
Response Elements (ARE) were used as stable luciferase 
reporter cells (AREc32) to report NRF2 dependent 
transcription [98]. Briefly, AREc32 cells were seeded in 
quadruplicate in 24-well plates at a density of 0.5 × 105 
cells per well and allowed to attach for 24 h. Next day, 
cells were washed with pre-warmed PBS, treated as 
required and further allowed to incubate for the desired 
time period. Towards the end of treatments, 250 μL of the 
reconstituted luciferase reagent (Bright GloTM Luciferase, 
Promega) was added in each well containing 250 μL of 
pre-existing media and the plate incubated at 37°C for 10 
min. 100 μL of the cell lysate was transferred to opaque 
white bottom 96-well plate for luminescence detection in 
a luminometer (MODULUSTM, Promega) while 50μL was 
subjected to Bradford assay to estimate protein content for 
the normalization of luminescence signal.
Cytotoxicity assay
Cytotoxicity assays were performed using 
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium 
Bromide (MTT). Briefly, cells were seeded in triplicates 
at a density of 0.5 × 104cells in 96-well plate and allowed 
to attach for 24 h. Following this, old media was removed 
and 80 μL of media containing relevant drugs was added 
and the plate incubated for the required period of time. 
On the day of assay, 20 μL of the 5mg/mL MTT stock 
was added to each well and the plate further incubated 
for 4 h. Following this, the old media with MTT was 
removed, cells gently washed with pre-warmed PBS and 
100 μL of DMSO added to solubilize the internalized 
MTT by shaking the plate over an orbital shaker for 15 
min. Absorbance of the released dye was measured and 
recorded using multiplate reader (MODULUS™, Promega) 
at 540 nm.
Immunocytochemistry/immunolabelling
For immunocytochemistry, exponentially growing 
cells were seeded at a density of 5 × 104 cells in media 
onto poly-L lysine (Sigma-Aldrich) coated cover slips 
placed in a 12-well tissue culture plates and allowed to 
attach for 24 h. Following relevant treatments, cells were 
washed three times with ice cold PBS and fixed in 3.5% 
paraformaldehyde in standard PBS at room temperature 
for 30 min. Next, cells were gently washed twice with 
1 ml of PBS, permeabilized with 0.3% triton X-100 in 
PBS for 10min, and following three washes with PBS, 
blocked with a solution containing 1% goat serum, 1% 
bovine serum albumin and 0.05% Triton X-100 in PBS for 
30 min. Cells were then incubated with relevant primary 
antibody (Table 1) diluted in blocking solution for 1 h, 
washed three times with 0.1% Triton X-100/PBS for 5 
min, and then incubated with Alexa Fluor 488 or 568- 
conjugated goat anti-rabbit secondary antibody (Table 1) 
for 30 min. After subsequent three washes with the 0.1% 
Triton X-100 in PBS for 5 min, cover slips with cells were 
mounted on slide using 4',6-Diamidino-2-Phenylindole, 
Dihydrochloride (DAPI)-containing mounting reagent 
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(Life technologies) and imaged under relevant filters with 
a Leica DMiRe2 electronic microscope.
Imaging and analysis
Quantitative analysis of raw immunoblots was 
performed by capturing the images in high resolution 
TIFF format files using a charge-coupled-device camera 
(AxioCam MRc, Carl Zeiss) and subjected to Gelpro 
analysis software, version 3.1 (Gelpro Media Cybernetics) 
for integrated optimal densitometry. Fluorescence 
images of immunocytochemistry were collected under 
relevant excitation and emission filters depending on the 
fluorotype under Leica DMiRe2 electronic microscope 
equipped with iXonEM +897 EMCCD camera (ANDOR 
Technologies Ltd). Images were analyzed using 
multidimensional microscopy software Andor Module iQ 
Core. Colocalization assay was performed and determined 
with software integral features supplied by Andor IQ core 
software. Data were generally expressed as mean ± S.D. 
for individual sets of experiments.
Bisulfite sequencing and promoter methylation 
analysis
Bisulfite conversion of the genomic DNA extracted 
from ovarian cell lines was performed using EpiTect 
Fast LyseAll Bisulfite Kit (Qiagen) using manufacturer’s 
instructions. Briefly, ovarian cancer cells were seeded in 
60 mm plates and allowed to attach for 24 h. Following 
this, cells were exposed to different treatments for 
required period of time, trypsinized, centrifuged and 
pellets suspended in 150 μL cold PBS. From this mixture, 
10 μL was used for DNA extraction using the lysis 
buffer supplied in the kit, bisulfite converted following 
manufacturer’s instructions and the final elute quantified 
using AstraGene microvolume spectrophotometer 
(AstraNet) to obtain a concentration of 20 ng/μL genomic 
DNA. Next, 100 ng of the extracted DNA was subjected 
to PCR amplification (Myfi mix, Bioline), using bisulfite 
specific primers (Table 3) applying PCR conditions of 
95°C for 7 min for initial denaturation followed by 30 
cycles of 95°C for 30 s denaturation, 50°C for 30 s for 
annealing and 72°C for 90 s for extension and a final 
extension at 72°C for 10 min. Unconverted DNA extracted 
from same cells were used as negative controls. The 
products were run on 1.5% agarose gel and analyzed for 
integrity and size (Supplementary Figure S3) and sent to 
a commercial sequencing service (www.dnaseq.co.uk) to 
identity the sequences. For in silico analysis of promoter 
methylation and prediction of CpG islands in NRF2 
promoter, the Methprimer (www.urogene.org) online 
resource was used. Firstly, a 1.5 kb human NRF2 promoter 
sequence was retrieved from Ensembl genome browser 
(Ensembl.org) and provided as input to the Methprimer 
software. Following further analysis, a 270 bp region with 
18 predicted potential methylated sites was identified. The 
primers, which were specific for Bisulfite converted DNA, 
were selected and ordered (Table 3) and used to amplify 
270 bp region of genomic DNA isolated from PEO4, 
OVCAR4 and SKOV3 cells following relevant treatments.
Quantitative real-time PCR (qRT PCR)
Quantitative real-time PCR (qRT PCR) was 
performed using Taqman® Universal master mix (Life 
technologies). The probes and primers for human NRF2 
(Hs00975961_g1), HO-1 (Hs00157965_m1) and 18s RNA 
(Hs03928992_g1) were obtained from life technologies 
and previously validated by the manufacturers. For 
GCLM, custom-made primers were used with the 
sequence and probe listed in Table 3. Real time PCR, 
analysis and processing of obtained data were performed 
by Stratagene Mx 3000P PCR amplification machine and 
built-in software (Agilent Technologies). Briefly, PEO4, 
OVCAR4 and SKOV3 cell lines were seeded in 60 mm 
plates and grown until 70% confluent. Following this, cells 
were washed once with warm PBS and new media with 
required treatments added for the desired period of time. 
Total RNA was extracted from treated cells using Trisure 
(Bioline) and its integrity and quality was determined 
by agarose gel electrophoresis and quantified using 
AstraGene microvolume spectrophotometer (AstraNet). 
500 ng RNA was next used to convert to cDNA with the 
Affinity Script cDNA synthesis kit (Agilent Technologies). 
The cDNA was subjected to qRT PCR using relevant 
probes and primers as listed in Table 3.
Statistical analysis
All statistical analysis were performed using 
statistical software SPSS (IBM, version 22). Test for 
normality of data was determined by Shapiro-Wilk and 
Kolmogorov and Smirnov tests. The significance (p value) 
of differences of pooled results was determined by either 
independent t tests or One WAY ANOVA followed by post 
hoc Tukey’s tests. Significance was defined as * = p< 0.05, 
** = p<0.01, *** = p<0.001.
Glutathione assay
Total cellular Glutathione (GSH) levels were 
determined by using the GSH assay kit (Sigma) according 
to the protocols described by Tietze F, 1969 [99].
Bioinformatics methods and in vivo analysis
Microarray data on gene expression (GSE31432; 
NCBI Gene Expression Omnibus https://www.ncbi.
nlm.nih.gov/geo) following Trastuzumab (20 mg/kg), 
Pertuzumab (20 mg/kg) and the combination treatment 
from SKOV3 tumor xenografts in mice were used [32, 
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100]. In this paper, we focused on gene expression 
relating to the NRF2 network and downstream targets, as 
well as the glutathione and epigenetics signatures, which 
are modulated by the anti-HER2 therapies. Different 
visualization methods were used to represent the results 
of statistical analysis of expression data. In addition 
to typical clustering of expression data in the form of 
heatmaps, we generated and analyzed volcano plots, Venn 
diagrams and signaling network maps. Volcano plots 
represent fold change in gene expression level together 
with the statistical significance of this change [32, 100, 
101]. Signaling network maps combine gene expression 
data with protein signaling network downloaded from 
the KEGG database (http://www.genome.jp/kegg/), the 
work of Papp D et al, 2012 [102] and other knowledge-
based approach and sources [103–106]. We used the R 
programming language for statistical processing of the 
data (Student's t-test) with the Bioconductor package for 
processing the data and Cytoscape (http://www.cytoscape.
org) with CytoKEGG plugin for network illustration 
to integrate the gene expression data with the KEGG 
signaling networks and also the NRF2-related interactome 
and regulome [102], downloaded and imported into the 
network model to Cytoscape. From there, the list of genes 
associated with the pathways were extracted and used 
in R to obtain the required gene expression values for 
further analysis. The means of the expression values in 
drug and control samples were calculated and followed 
by a Student's t-test to calculate the p-values for the fold 
changes. We then generated the heatmaps showing the 
log2 fold-change that the drugs caused to expression of the 
genes. We also used the fold-change data and the p-values 
to create volcano plots for the different drugs treatments 
using all the genes in the dataset and only for the genes 
associated with the different pathways examined and 
reported. Lastly, the ratios were exported to Cytoscape to 
color the nodes in the network visualization.
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